US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Cybin Inc

11.60

-0.1600-1.36%

Pre-market: 12.000.4000+3.45%04:59 EDT

Volume:1.14M

Turnover:13.44M

Market Cap:847.50M

PE:-2.86

High:12.17

Open:11.76

Low:11.50

Close:11.76

52wk High:14.35

52wk Low:3.76

Shares:73.06M

Float Shares:59.74M

Volume Ratio:0.68

T/O Rate:1.91%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.0491

EPS(LYR):-3.8923

ROE:-86.94%

ROA:-44.38%

PB:3.50

PE(LYR):-2.98

Loading ...

Overview Company News Filings

Cybin (HELP) As Phase 3 Enrollment Progresses, The Undervalued Narrative Holds

Simply Wall St.

Cybin Inc Expected to Post a Loss of 93 Cents a Share - Earnings Preview

Calendar of U.S. Earnings Expected in the Week Ahead

Helus Pharma Closes $50 Million Underwritten Offering

MT Newswires Live

Helus Pharma Says Enrollment Tops 86% for Phase 3 HLP003 Trial in Major Depressive Disorder

MT Newswires Live

Helus Pharma Prices $50 Million Underwritten Offering

MT Newswires Live

Helus Pharma prices 10.31M common shares at $4.85 in public offering

We Think Cybin (NASDAQ:HELP) Needs To Drive Business Growth Carefully

Simply Wall St.

H.C. Wainwright Keeps Their Buy Rating on Helus Pharma (HELP)

How Leadership Turnover at Helus Pharma Will Impact Cybin’s (HELP) Execution Narrative

Simply Wall St.

Psychedelic Stocks Surge After Trump Supports Using Drugs Like LSD for Mental Health

H.C. Wainwright Sticks to Its Buy Rating for Helus Pharma (HELP)

Helus ‘welcomes’ Executive Order for accelerating psychedelic research

Psychedelic Drug Stocks Surge with Compass Pathways up 37%; Atai Beckley up 28%. Trump Accelerates Psychedelic Research With $50 Million Ibogaine Commitment

Benzinga Earnings

Helus Pharma announces Cola is stepping down as CEO, appoints So as Interim CEO

Helus Pharma appoints Kramer as Senior Vice President, Medical Affairs

Helus Pharmaceuticals : TD Cowen Initiates Coverage With Buy Rating; Target Price $8

THOMSON REUTERS

Helus Pharma initiated with a Buy at TD Cowen

Analysts Conflicted on These Healthcare Names: Johnson & Johnson (JNJ), BeOne Medicines (ONC) and Helus Pharma (HELP)

H.C. Wainwright Reaffirms Their Buy Rating on Cybin (HELP)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/HELP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HELP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELP\",,,,,undefined,":{"symbol":"HELP","market":"US","secType":"STK","nameCN":"Cybin Inc","latestPrice":11.6,"timestamp":1788292800000,"preClose":11.76,"halted":0,"volume":1140718,"hourTrading":{"tag":"盘前","latestPrice":12,"preClose":11.6,"latestTime":"04:59 EDT","volume":2278,"amount":27198.641156,"timestamp":1788339549962,"change":0.4,"changeRate":0.034483,"amplitude":0.02931},"delay":0,"changeRate":-0.01360544217687076,"floatShares":59740268,"shares":73060200,"eps":-4.049081,"marketStatus":"Pre-Mkt","change":-0.16,"latestTime":"09-02 05:51:38 EDT","open":11.76,"high":12.165,"low":11.5,"amount":13435889.927099999,"amplitude":0.056548,"askPrice":12,"askSize":100,"bidPrice":10.06,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.049081,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788355800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":11.6,"preHourTrading":{"tag":"盘前","latestPrice":12,"preClose":11.6,"latestTime":"04:59 EDT","volume":2278,"amount":27198.641156,"timestamp":1788339549962,"change":0.4,"changeRate":0.034483,"amplitude":0.02931},"postHourTrading":{"tag":"盘后","latestPrice":11.55,"preClose":11.6,"latestTime":"19:50 EDT","volume":2375,"amount":27514.3797,"timestamp":1788306625634,"change":-0.05,"changeRate":-0.00431,"amplitude":0.00431},"volumeRatio":0.6818730668472421,"impliedVol":1.0984,"impliedVolPercentile":0.3373},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELP\",,,,,undefined,":{"symbol":"HELP","floatShares":59740268,"roa":"-44.38%","roe":"-86.94%","lyrEps":-3.892309,"volumeRatio":0.6818730668472421,"shares":73060200,"dividePrice":0,"high":12.165,"amplitude":0.056548,"preClose":11.76,"low":11.5,"week52Low":3.76,"pbRate":"3.50","week52High":14.35,"institutionHeld":0,"latestPrice":11.6,"eps":-4.049081,"divideRate":0,"volume":1140718,"delay":0,"ttmEps":-4.049081,"open":11.76,"prevYearClose":8.18,"prevWeekClose":12.18,"prevMonthClose":11.76,"prevQuarterClose":6.61,"fiveDayClose":13.985,"twentyDayClose":9.28,"sixtyDayClose":4.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"HELP","fiscalQuarterEnding":"2026/06","expectedEps":-0.8,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-0.91},{"market":"US","date":"2026-06-29","symbol":"HELP","fiscalQuarterEnding":"2026/03","expectedEps":-1.04,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1782705600000,"reportTimeType":"pre","actualEps":-1.02},{"market":"US","date":"2026-02-13","symbol":"HELP","fiscalQuarterEnding":"2025/12","expectedEps":-0.53,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1770958800000,"reportTimeType":"pre","actualEps":-0.72}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.8,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":10,"updateTime":1785211200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HELP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HELP","date":"2026-08-31","current":-2.864848,"percent":0.030864,"low":-5.968006,"twenty":-4.17863,"median":-2.60923,"eighty":-1.928869,"high":-1.57152,"avg":-2.905171,"sd":1.072495,"marketCap":889872894},"quantilePoints":[{"date":"2026-01-09","current":-4.237274,"twenty":-4.344211,"median":-4.257397,"eighty":-4.216576,"marketCap":367789729},{"date":"2026-01-16","current":-4.513243,"twenty":-4.471847,"median":-4.329263,"eighty":-4.240723,"marketCap":391743470},{"date":"2026-01-23","current":-4.432752,"twenty":-4.4477,"median":-4.415504,"eighty":-4.256821,"marketCap":384756963},{"date":"2026-01-30","current":-3.892312,"twenty":-4.44425,"median":-4.332138,"eighty":-4.197028,"marketCap":337847553},{"date":"2026-02-06","current":-3.369121,"twenty":-4.439651,"median":-4.243023,"eighty":-3.91531,"marketCap":292435253},{"date":"2026-02-13","current":-3.403617,"twenty":-4.425853,"median":-4.199903,"eighty":-3.703734,"marketCap":295429471},{"date":"2026-02-20","current":-2.801935,"twenty":-4.400556,"median":-4.133785,"eighty":-3.477209,"marketCap":345246985},{"date":"2026-02-27","current":-3.151162,"twenty":-4.339612,"median":-3.892312,"eighty":-3.128422,"marketCap":388277769},{"date":"2026-03-06","current":-2.290278,"twenty":-4.333863,"median":-3.768701,"eighty":-3.012284,"marketCap":282201883},{"date":"2026-03-13","current":-2.083178,"twenty":-4.318914,"median":-3.656589,"eighty":-2.772698,"marketCap":256683628},{"date":"2026-03-20","current":-1.953233,"twenty":-4.27062,"median":-3.450978,"eighty":-2.359311,"marketCap":240672173},{"date":"2026-03-27","current":-1.888261,"twenty":-4.241873,"median":-3.369121,"eighty":-2.142465,"marketCap":232666446},{"date":"2026-04-02","current":-2.026327,"twenty":-4.237274,"median":-3.151162,"eighty":-1.973537,"marketCap":249678617},{"date":"2026-04-10","current":-2.127847,"twenty":-4.214276,"median":-3.041521,"eighty":-2.026327,"marketCap":262187565},{"date":"2026-04-17","current":-2.233427,"twenty":-4.185529,"median":-2.883151,"eighty":-2.079117,"marketCap":275196872},{"date":"2026-04-24","current":-2.334946,"twenty":-4.168281,"median":-2.755237,"eighty":-2.079117,"marketCap":287705821},{"date":"2026-05-01","current":-2.156272,"twenty":-4.099289,"median":-2.473013,"eighty":-2.079117,"marketCap":265690071},{"date":"2026-05-08","current":-2.168454,"twenty":-3.949806,"median":-2.332915,"eighty":-2.083178,"marketCap":267191145},{"date":"2026-05-15","current":-2.054753,"twenty":-3.892312,"median":-2.278095,"eighty":-2.070996,"marketCap":253181122},{"date":"2026-05-22","current":-1.867957,"twenty":-3.817571,"median":-2.245609,"eighty":-2.001963,"marketCap":230164657},{"date":"2026-05-29","current":-1.823288,"twenty":-3.808372,"median":-2.233427,"eighty":-1.952421,"marketCap":224660719},{"date":"2026-06-05","current":-1.798924,"twenty":-3.746279,"median":-2.217184,"eighty":-1.904504,"marketCap":221658571},{"date":"2026-06-12","current":-1.644614,"twenty":-3.694535,"median":-2.188759,"eighty":-1.887449,"marketCap":202644969},{"date":"2026-06-18","current":-1.859835,"twenty":-3.668088,"median":-2.162363,"eighty":-1.864708,"marketCap":229163941},{"date":"2026-06-26","current":-2.444587,"twenty":-3.642791,"median":-2.156272,"eighty":-1.87283,"marketCap":301215485},{"date":"2026-07-02","current":-2.630171,"twenty":-3.565692,"median":-2.168454,"eighty":-1.879327,"marketCap":389260009},{"date":"2026-07-10","current":-2.776757,"twenty":-3.45355,"median":-2.19891,"eighty":-1.885824,"marketCap":410954437},{"date":"2026-07-17","current":-2.948472,"twenty":-3.424315,"median":-2.233427,"eighty":-1.891509,"marketCap":436367909},{"date":"2026-07-24","current":-3.237455,"twenty":-3.399137,"median":-2.237487,"eighty":-1.896382,"marketCap":479136922},{"date":"2026-07-31","current":-3.40917,"twenty":-3.401377,"median":-2.263883,"eighty":-1.897194,"marketCap":504550394},{"date":"2026-08-07","current":-4.648869,"twenty":-3.432324,"median":-2.290278,"eighty":-1.901255,"marketCap":688023265},{"date":"2026-08-14","current":-4.795455,"twenty":-3.679587,"median":-2.339007,"eighty":-1.904504,"marketCap":709717693},{"date":"2026-08-21","current":-4.514739,"twenty":-3.872812,"median":-2.466832,"eighty":-1.909377,"marketCap":772941452},{"date":"2026-08-28","current":-5.650082,"twenty":-4.154483,"median":-2.567348,"eighty":-1.928869,"marketCap":967316677},{"date":"2026-08-31","current":-5.197734,"twenty":-4.17863,"median":-2.60923,"eighty":-1.928869,"marketCap":889872894}],"updateTime":1788333793084},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2647343036","title":"Cybin (HELP) As Phase 3 Enrollment Progresses, The Undervalued Narrative Holds","url":"https://stock-news.laohu8.com/highlight/detail?id=2647343036","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647343036?lang=en_us&edition=fundamental","pubTime":"2026-06-29 03:08","pubTimestamp":1782673723,"startTime":"0","endTime":"0","summary":"Cybin (HELP) is drawing fresh attention after reporting that enrollment in its APPROACH Phase 3 trial for HLP003 in major depressive disorder has surpassed 86%, a key marker in its broader PARADIGM program.\nSee our latest analysis for Cybin.\nThe recent APPROACH trial update comes after a sharp short term rebound in Cybin's 1 week and 1 month share price returns of 38.76% and 42.42% respectively. This is set against a year to date share price return that is still down 21.74% and a 5 year total...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/cybin-help-as-phase-3-enrollment-progresses-the-undervalued","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/cybin-help-as-phase-3-enrollment-progresses-the-undervalued","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646436701","title":"Cybin Inc Expected to Post a Loss of 93 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2646436701","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646436701?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:02","pubTimestamp":1782504142,"startTime":"0","endTime":"0","summary":"Cybin Incexpected to post a loss of93cents a share - Earnings PreviewCybin IncHELP.NLBis expected to  show no change in quarterly revenue when it reports  results on June 29 (estimated) for the period","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nL8N42Y1LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646355768","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2646355768","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646355768?lang=en_us&edition=fundamental","pubTime":"2026-06-26 18:00","pubTimestamp":1782468000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Company                                   Symbol     Quarter  Mean  Report Time. Constellation Brands Inc. Class A                1Q      3.23       AMC. NIKE Inc. Class B                                4Q       .13   4:15 PM. FactSet Research Syss Inc.                       3Q      4.45   6:00 AM. MSC Indus Direct Co. Inc. Class A                3Q      1.27   6:30 AM. Lindsay Corp.                                    3Q      1.14   6:45 AM Dow Jones NewswiresJune 26, 2026 06:00 ET Copyright  2026 Dow Jones & Company, Inc.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKE","LU2065732104.USD","LNN","APOG","BK4104","FDS","LU2065171402.SGD","AVAV","LU1585245621.USD","PRGS","GBX","GIS","BK4559","BK4007","MSM","BK4082","BK4123","LU0128525689.USD","LU1267930573.SGD","LU2095319765.USD","LU0786609619.USD","LU2552382058.USD","BK4146","BK4112","CNXC","LU0310800379.SGD","BK4581","AVXX","BK4212","LU0128525929.USD","HELP","LU1303367103.USD","UNF","XAIR","BK4532","LU1430594728.SGD","BK4533","BK4226","BK4108","IE00BFXG0V08.USD","LU2210150020.SGD","LU1267930227.SGD","FC","BK4588","LU2552382215.SGD","LU0823411888.USD","LU0029864427.USD","STZ","AMC","LU0889566641.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646070805","title":"Helus Pharma Closes $50 Million Underwritten Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2646070805","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646070805?lang=en_us&edition=fundamental","pubTime":"2026-06-25 21:50","pubTimestamp":1782395442,"startTime":"0","endTime":"0","summary":"Helus Pharma  closed a previously announced underwritten offering that raised $50 million in gross proceeds through the sale of about 10.3 million common shares at $4.85 each, the company said Thursday.The company said it paid underwriters a $3 million cash commission.Helus Pharma said it plans to use the net proceeds to advance its HLP003 program for major depressive disorder, HLP004 for generalized anxiety disorder, and HLP005, as well as for working capital and other corporate purposes.The company said it expects Phase 3 APPROACH data from the HLP003 program in the fourth quarter of 2026.Shares of the company were up 4% in early Thursday trading.Price: 5.38, Change: +0.29, Percent Change: +5.70","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645089714","title":"Helus Pharma Says Enrollment Tops 86% for Phase 3 HLP003 Trial in Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2645089714","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645089714?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:29","pubTimestamp":1782300560,"startTime":"0","endTime":"0","summary":"Helus Pharma  said Wednesday that enrollment in its phase 3 clinical trial evaluating HLP003 for the adjunctive treatment of major depressive disorder has surpassed 86%.The company said it remains on track to report topline data from the study in Q4.Shares of the company were up 7.8% in Wednesday's premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645894086","title":"Helus Pharma Prices $50 Million Underwritten Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2645894086","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645894086?lang=en_us&edition=fundamental","pubTime":"2026-06-24 18:37","pubTimestamp":1782297473,"startTime":"0","endTime":"0","summary":"Helus Pharma  has priced an underwritten public offering of 10.3 million common shares at $4.85 apiece for aggregate gross proceeds of $50 million, the company said Wednesday.The company said it will use the proceeds to advance its HLP003, HLP004 and HLP005 programs, including HLP003 for major depressive disorder, with phase 3 data expected in the fourth quarter.The offering is expected to close Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645012894","title":"Helus Pharma prices 10.31M common shares at $4.85 in public offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2645012894","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645012894?lang=en_us&edition=fundamental","pubTime":"2026-06-24 18:35","pubTimestamp":1782297320,"startTime":"0","endTime":"0","summary":"Helus Pharma (HELP) is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the company at an ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/helus-pharma-prices-10-31m-common-shares-at-4-85-in-public-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/helus-pharma-prices-10-31m-common-shares-at-4-85-in-public-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644748908","title":"We Think Cybin (NASDAQ:HELP) Needs To Drive Business Growth Carefully","url":"https://stock-news.laohu8.com/highlight/detail?id=2644748908","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644748908?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:42","pubTimestamp":1781692941,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/we-think-cybin-nasdaqhelp-needs-to-drive-business-growth-car","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/we-think-cybin-nasdaqhelp-needs-to-drive-business-growth-car","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QQQ","NDX","QQQJ","TQQQ","MNQmain","PSQ","NVIW.SI","BK4007","GPIQ","QQQE","FTEC","QDTE","QID","QQQM","QLD","NQmain","QYLG","QQQY","TECS","JEPQ","ONEQ","HELP","SQQQ","TQQY",".IXIC","QQQA","IYW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631584986","title":"H.C. Wainwright Keeps Their Buy Rating on Helus Pharma (HELP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2631584986","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631584986?lang=en_us&edition=fundamental","pubTime":"2026-04-29 00:35","pubTimestamp":1777394137,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Helus Pharma, with a price target of $95.00. According...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-helus-pharma-help-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-helus-pharma-help-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629006290","title":"How Leadership Turnover at Helus Pharma Will Impact Cybin’s (HELP) Execution Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2629006290","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629006290?lang=en_us&edition=fundamental","pubTime":"2026-04-23 14:14","pubTimestamp":1776924878,"startTime":"0","endTime":"0","summary":"Cybin’s subsidiary Helus Pharma recently saw Executive Chairman and Co‑founder Eric So re‑assume the role of Interim CEO after the board requested Michael Cola’s departure, while also adding neuroscience veteran Dr. Ken Kramer as Senior Vice President of Medical Affairs.\nThis combination of a board-driven leadership change and a high-profile medical affairs hire could influence how investors assess Helus’ execution capabilities within Cybin’s broader clinical platform.\nWe’ll now examine how...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/how-leadership-turnover-at-helus-pharma-will-impact-cybins-h","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/how-leadership-turnover-at-helus-pharma-will-impact-cybins-h","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HELP","BK4007","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629779874","title":"Psychedelic Stocks Surge After Trump Supports Using Drugs Like LSD for Mental Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2629779874","media":"Dow Jones","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629779874?lang=en_us&edition=fundamental","pubTime":"2026-04-21 09:54","pubTimestamp":1776736485,"startTime":"0","endTime":"0","summary":"An executive order aims to speed up how quickly psychedelic drugs for mental illness can move through the regulatory process","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Trump Supports Using Drugs Like LSD for Mental Health","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","HELP","ATAI","BK4139","DFTX","GHRS","BK4007","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629202777","title":"H.C. Wainwright Sticks to Its Buy Rating for Helus Pharma (HELP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629202777","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629202777?lang=en_us&edition=fundamental","pubTime":"2026-04-21 01:37","pubTimestamp":1776706649,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Helus Pharma, with a price target of $95.00. Trucchio ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-helus-pharma-help-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-helus-pharma-help-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628724864","title":"Helus ‘welcomes’ Executive Order for accelerating psychedelic research","url":"https://stock-news.laohu8.com/highlight/detail?id=2628724864","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628724864?lang=en_us&edition=fundamental","pubTime":"2026-04-20 22:47","pubTimestamp":1776696420,"startTime":"0","endTime":"0","summary":"Helus Pharma (HELP) welcomed the White House Executive Order aimed at accelerating research, regulatory pathways, and patient access to psychedelic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/helus-welcomes-executive-order-for-accelerating-psychedelic-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/helus-welcomes-executive-order-for-accelerating-psychedelic-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628511527","title":"Psychedelic Drug Stocks Surge with Compass Pathways up 37%; Atai Beckley up 28%. Trump Accelerates Psychedelic Research With $50 Million Ibogaine Commitment","url":"https://stock-news.laohu8.com/highlight/detail?id=2628511527","media":"Benzinga Earnings","labels":["movement","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628511527?lang=en_us&edition=fundamental","pubTime":"2026-04-20 22:32","pubTimestamp":1776695576,"startTime":"0","endTime":"0","summary":"On Saturday, President Donald Trump signed an executive order directing the U.S. Food and Drug Administration to move faster on reviews tied to psychedelic-based research and treatment, including...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/04/51902644/trump-accelerates-psychedelic-research-with-50-million-ibogaine-commitment","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Trump Accelerates Psychedelic Research With $50 Million Ibogaine Commitment","news_tag":"movement,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATAI","HELP","CMPS","DFTX","GHRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628301723","title":"Helus Pharma announces Cola is stepping down as CEO, appoints So as Interim CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2628301723","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628301723?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:41","pubTimestamp":1776688884,"startTime":"0","endTime":"0","summary":"Helus Pharma (HELP) announced that Michael Cola is stepping down as Chief Executive Officer, effective immediately, at the request of the Board of ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/helus-pharma-announces-cola-is-stepping-down-as-ceo-appoints-so-as-interim-ceo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/helus-pharma-announces-cola-is-stepping-down-as-ceo-appoints-so-as-interim-ceo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627297166","title":"Helus Pharma appoints Kramer as Senior Vice President, Medical Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2627297166","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627297166?lang=en_us&edition=fundamental","pubTime":"2026-04-16 19:38","pubTimestamp":1776339507,"startTime":"0","endTime":"0","summary":"Helus Pharma (HELP) announced the appointment of Dr. Ken Kramer, PhD as Senior Vice President, Medical Affairs, effective immediately. Most recentl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/helus-pharma-appoints-kramer-as-senior-vice-president-medical-affairs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/helus-pharma-appoints-kramer-as-senior-vice-president-medical-affairs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627432989","title":"Helus Pharmaceuticals : TD Cowen Initiates Coverage With Buy Rating; Target Price $8","url":"https://stock-news.laohu8.com/highlight/detail?id=2627432989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627432989?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:01","pubTimestamp":1776078107,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nFWN40W0MW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627439249","title":"Helus Pharma initiated with a Buy at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2627439249","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627439249?lang=en_us&edition=fundamental","pubTime":"2026-04-13 17:50","pubTimestamp":1776073828,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Ritu Baral initiated coverage of Helus Pharma (HELP) with a Buy rating and $8 price target The firm believes the company’s positiv...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/helus-pharma-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/helus-pharma-initiated-with-a-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","BK4007","COWN","TD","BK4127","HELP","BK4566","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627439257","title":"Analysts Conflicted on These Healthcare Names: Johnson & Johnson (JNJ), BeOne Medicines (ONC) and Helus Pharma (HELP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2627439257","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627439257?lang=en_us&edition=fundamental","pubTime":"2026-04-13 17:50","pubTimestamp":1776073807,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Johnson & Johnson (JNJ), BeOne Medicines (ONC) and Helus Pharma (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-johnson-johnson-jnj-beone-medicines-onc-and-helus-pharma-help-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-johnson-johnson-jnj-beone-medicines-onc-and-helus-pharma-help-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1585245621.USD","BK4526","ONC","LU1221951046.USD","LU1778281490.HKD","IE00BBT3K403.USD","LABU","IE000BZT7R73.USD","LU1261432733.SGD","SGXZ57979304.SGD","LU0289739699.SGD","BK4533","IE0009355771.USD","IE00BSNM7G36.USD","HCSG","LU0345769128.USD","LU1162221912.USD","LU1894683264.USD","LU1066053197.SGD","IE0001KFT4U8.USD","LU2471134952.CNY","LU0792757196.USD","LU1674673428.USD","IE00B3PB1722.GBP","LU2133065610.SGD","SG9999002224.SGD","LU1244550221.USD","LU0029874061.USD","BK4550","LU0234572021.USD","LU2750360997.AUD","LU1043141123.HKD","LU1496350502.SGD","HELP","IE00BFXG1179.USD","BK4588","XLV","JNJ","LU0985320562.USD","MDCO","LU0122379950.USD","LU1023059063.AUD","IE00B3T34201.USD","IE00B2B36J28.USD","LU2471134879.HKD","IE00BJT1NW94.SGD","XBI","LU0124676726.USD","LU2129689514.USD","LU0994945656.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617753521","title":"H.C. Wainwright Reaffirms Their Buy Rating on Cybin (HELP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617753521","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617753521?lang=en_us&edition=fundamental","pubTime":"2026-03-06 00:16","pubTimestamp":1772727404,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Cybin today and set a price target of $95.00. Trucchio covers the Healthcare se...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-cybin-help-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-cybin-help-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":41,"code":"91000000","status":"200"}]}}